Your account is not claimed yet. You can sign up with ORCID to claim your account.

Loek A W de Jong

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 12

Top Venues

Cancer chemotherapy and pharmacology

British journal of clinical pharmacology

Cancers

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Loek A W de Jong, Marie Lambert, Nielka P van Erp, Lukas de Vries, Etienne Chatelut, Petronella B Ottevanger
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer chemotherapy and pharmacology 91 (3) (2023)
Jeffrey Strik, Loek A W de Jong, Joost Sijm, Ingrid M E Desar, Nielka P van Erp
Effect of aprepitant on etoposide pharmacokinetics in patients with testicular cancer: a pharmacokinetic study to determine the absence of a clinically relevant interaction. Clinical pharmacology and therapeutics (2023)
Eline L Giraud, Loek A W de Jong, Erik van den Hombergh, Suzanne E J Kaal, Nielka P van Erp, Ingrid M E Desar
Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant? Cancers 15 (11) (2023)
Loek A W de Jong, Marie Lambert, Nielka P van Erp, Lukas de Vries, Etienne Chatelut, Petronella B Ottevanger
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer chemotherapy and pharmacology 91 (3) (2023)
Loek A W de Jong, Marie Lambert, Nielka P van Erp, Lukas de Vries, Etienne Chatelut, Petronella B Ottevanger
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer chemotherapy and pharmacology 91 (3) (2023)
Loek A W de Jong, Marie Lambert, Nielka P van Erp, Lukas de Vries, Etienne Chatelut, Petronella B Ottevanger
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer chemotherapy and pharmacology (2023)
Loek A W de Jong, Marie Lambert, Nielka P van Erp, Lukas de Vries, Etienne Chatelut, Petronella B Ottevanger
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer chemotherapy and pharmacology 91 (3) (2023)
Loek A W de Jong, Nielka P van Erp, Lana Bijelic
Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to Proof. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (7) (2021)
Loek A W de Jong, Fortuné M K Elekonawo, Marie Lambert, Jan Marie de Gooyer, Henk M W Verheul, David M Burger, Johannes H W de Wilt, Etienne Chatelut, Rob Ter Heine, Philip R de Reuver, Andre J A Bremers, Nielka P van Erp
Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study. Cancer chemotherapy and pharmacology 86 (1) (2020)
Loek A W de Jong, Paul D van der Linden, Monique M B Roukens, Ewoudt M W van de Garde, Alike W van der Velden, Stephanie Natsch, null null
Consecutive antibiotic use in the outpatient setting: an extensive, longitudinal descriptive analysis of antibiotic dispensing data in the Netherlands. BMC infectious diseases 19 (1) (2019)
Loek A W de Jong, Nielka P van Erp
Reply to 'Hyperthermic intraperitoneal chemotherapy with oxaliplatin-Still not standard of care for patients with colorectal peritoneal metastases' by Julianov and Saroglu. British journal of clinical pharmacology 85 (8) (2019)
Loek A W de Jong, Fortuné M K Elekonawo, Philip R de Reuver, Andre J A Bremers, Johannes H W de Wilt, Frank G A Jansman, Rob Ter Heine, Nielka P van Erp
Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. British journal of clinical pharmacology 85 (1) (2018)

Loek A W de Jong.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Loek A W de Jong